YOKNE'AM ILLIT, Israel, June 5, 2024 /PRNewswire/ -- Lumenis Be. Ltd., a leading energy-based medical device company for aesthetic and eye care solutions, is proud to announce the launch of its breakthrough laser system designed to combat hair loss. Recently cleared by the Food and Drug Administration (FDA), FoLix becomes the first and only fractional laser choice for safe, effective, and natural hair loss treatment for women and men in the United States[1]..

以色列YOKNE'AM ILLIT，2024年6月5日/PRNewswire/--Lumenis Be.Ltd.是一家领先的美容和眼部护理解决方案的能源医疗器械公司，很自豪地宣布推出其突破性的激光系统，旨在对抗脱发。FoLix最近被美国食品和药物管理局（FDA）批准，成为美国男女安全、有效、自然脱发治疗的第一个也是唯一一个分数激光选择。。

Affecting more than 85% of men and 50% of women[2], hair loss remains a persistent, widespread challenge. FoLix's groundbreaking approach utilizes fractional laser and Lumenis' proprietary technology tailored for hair. This is a revolution for hair loss patients, offering results in 4-6 monthly sessions with no chemicals, needles, anesthesia, surgery, or downtime..

影响超过85%的男性和50%的女性（2），脱发仍然是一个持续的，广泛的挑战。FoLix开创性的方法利用分数激光和Lumenis为头发量身定制的专有技术。这是脱发患者的一场革命，每月4-6次，无需化学药品、针头、麻醉、手术或停工。。

FoLix's unique technology delivers precise pulses of laser that leverage the body's natural processes to stimulate hair follicles. Lumenis' pre-clinical and clinical studies measuring the laser's effect showed a positive impact on hair growth, with noticeable improvements in scalp hair appearance and an increase in hair count[3].

FoLix的独特技术提供精确的激光脉冲，利用人体的自然过程刺激毛囊。Lumenis测量激光效果的临床前和临床研究显示，对头发生长有积极影响，头皮毛发外观明显改善，头发数量增加（3）。

'Fractional lasers have been shown to have remarkable effects on the skin and now, finally, Lumenis has been able to harness that power and bring an innovative solution for hair stimulation,' said Dr. Marc Avram, a renowned hair transplant specialist and Clinical Professor of Dermatology at Weill Cornell Medical College (WCMC)..

威尔·康奈尔医学院（WCMC）著名毛发移植专家、皮肤病学临床教授马克·阿夫拉姆（MarcAvram）博士说：“分数激光已被证明对皮肤有显着影响，现在，Lumenis终于能够利用这种能量，为头发刺激带来创新解决方案。”。。

'With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers,' adds Dr. Neil Sadick, a world-leading dermatologist and researcher, and Clinical Professor of Dermatology at WCMC. 'FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.'.

世界领先的皮肤科医生和研究人员、WCMC皮肤病学临床教授尼尔·萨迪克（NeilSadick）博士补充说，随着脱发越来越受到关注，FoLix成为患者和提供者的关键创新FoLix提供了一个独特的机会，可以通过每月短暂的疗程帮助那些患有脱发的人，并将不适感降至最低，无需停机。”。

'At Lumenis, we're committed to transforming lives through science and innovation. FoLix is about more than just hair; it's about having the self-confidence to live life to the fullest,' said Lumenis CEO Tzipi Ozer-Armon. 'We are eager to collaborate with providers across the US to extend the influence and accessibility of this groundbreaking solution.'.

“在Lumenis，我们致力于通过科学和创新改变生活。FoLix不仅仅是头发；Lumenis首席执行官齐皮·奥泽尔·阿蒙（TzipiOzerArmon）说，这是关于拥有充分生活的自信我们渴望与美国各地的供应商合作，扩大这一开创性解决方案的影响力和可访问性。”。

For more information about FoLix please visit Lumenis.com/FoLix.

有关FoLix的更多信息，请访问Lumenis.com/FoLix。

About Lumenis

关于Lumenis

Lumenis is a global leader in the medical aesthetic market and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years, Lumenis' ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods, and creating solutions for previously untreatable conditions.

Lumenis是医疗美容市场的全球领导者，是开发和商业化创新能源技术（包括激光、强脉冲光（IPL）和射频（RF））的世界知名专家。50多年来，Lumenis开创性的产品重新定义了医疗方法，制定了技术和临床黄金标准，彻底改变了现有的治疗方法，并为以前无法治疗的疾病创造了解决方案。

Lumenis is a portfolio company of EQT Private Capital Asia. For more information regarding Lumenis' range of clinical solutions, please visit: www.lumenis.com..

Lumenis是EQT Private Capital Asia的投资组合公司。有关Lumenis系列临床解决方案的更多信息，请访问：www.Lumenis.com。。

About FoLix

关于FoLix

FoLix is a non-ablative fractional laser device to improve the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss.

FoLix是一种非烧蚀性分数激光装置，用于改善患有Fitzpatrick I至IV型皮肤的成年男性和女性的头皮毛发外观，他们正在寻求脱发治疗。

FoLix treatment could cause redness, swelling, scarring, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, active infection, fungal or bacterial diseases. See the system user manual for a complete list of contraindications and risks..

叶状处理可能导致发红，肿胀，疤痕和色素沉着改变。对于患有任何并发癌症或皮肤癌，活动性感染，真菌或细菌疾病史的患者，禁止使用FoLix。有关禁忌症和风险的完整列表，请参阅系统用户手册。。

*The physicians' testimonials represent a specific experience of a paid spokesperson. Experience of others may vary.

*医生的证明代表了付费发言人的特定经历。其他人的经验可能会有所不同。

1. See the 'About FoLix' section for the indication of use and relevant skin types.

1、有关使用指征和相关皮肤类型，请参阅“关于FoLix”部分。

2. Men's Hair Loss, American Hair Loss Association, https://www.americanhairloss.org/mens-hair-loss/; Hair Loss in Women, Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women.

2、男性脱发，美国脱发协会，https://www.americanhairloss.org/mens-hair-loss/；克利夫兰诊所，女性脱发，https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women.

3. As measured in 1-month and 3-month follow-ups following the last treatment session, compared to baseline. Data on file.

3.与基线相比，在最后一次治疗后的1个月和3个月随访中测量。文件中的数据。

Photo: https://mma.prnewswire.com/media/2430951/Lumenis_Be.jpg

Photo: https://mma.prnewswire.com/media/2430951/Lumenis_Be.jpg

Logo - https://mma.prnewswire.com/media/2431035/FoLix_by_Lumenis_Logo.jpg

标志https://mma.prnewswire.com/media/2431035/FoLix_by_Lumenis_Logo.jpg

Contact:

联系人：

Shani Peles

沙尼·贝利

shani.peles@lumenis.com

shani.peles@lumenis.com

+972 525974552

+972 525974552

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumenis-introduces-folix-the-first-fda-cleared-proprietary-fractional-laser-for-hair-loss-treatment-302164738.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/lumenis-introduces-folix-the-first-fda-cleared-proprietary-fractional-laser-for-hair-loss-treatment-302164738.html

SOURCE Lumenis Be Ltd.

SOURCE Lumenis有限公司。